Search research articles
Contact Us
Filters
Showing results (151-160 of 371) with videos related to
Page
of 38
Sort By:
British Journal of Clinical Pharmacology
|
May 23, 2020
Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases
Manon Belhassen, Florence Tubach, Christophe Hudry, et al.
Rheumatology (Oxford, England)
|
January 17, 2019
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
Ernest Choy, Roberto Caporali, Ricardo Xavier, et al.
Joint Bone Spine
|
December 27, 2005
Back problems in Parkinson's disease: an underestimated problem
Fabien Etchepare, Sylvie Rozenberg, Tristan Mirault, et al.
The Journal of Rheumatology
|
September 16, 2020
Prediction of Work Impact in Axial Spondyloarthritis by the Work Instability Scale: A Prospective Cohort Study of 101 Patients
Irina Cucos, Sabrina Dadoun, Charlotte Jacquemin, et al.
Joint Bone Spine
|
October 14, 2019
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
Bruno Fautrel, Manon Belhassen, Christophe Hudry, et al.
Orphanet Journal of Rare Diseases
|
March 12, 2015
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Linda Rossi-Semerano, Bruno Fautrel, Daniel Wendling, et al.
Journal of Medical Economics
|
April 12, 2016
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France
Francis Fagnani, Thao Pham, Pascal Claudepierre, et al.
Joint Bone Spine
|
November 1, 2019
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
Bruno Fautrel, Manon Belhassen, Christophe Hudry, et al.
Annals of the Rheumatic Diseases
|
June 5, 2016
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Georg Schett, Paul Emery, Yoshiya Tanaka, et al.
Current Medical Research and Opinion
|
March 31, 2017
Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)
Bruno Fautrel, Alejandro Balsa, Piet Van Riel, et al.
Page
of 38
Search research articles
Search
Showing results (151-160 of 371) with videos related to
Sort By:
Page
of 38
British Journal of Clinical Pharmacology
|
May 23, 2020
Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases
Manon Belhassen, Florence Tubach, Christophe Hudry, et al.
Rheumatology (Oxford, England)
|
January 17, 2019
Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
Ernest Choy, Roberto Caporali, Ricardo Xavier, et al.
Joint Bone Spine
|
December 27, 2005
Back problems in Parkinson's disease: an underestimated problem
Fabien Etchepare, Sylvie Rozenberg, Tristan Mirault, et al.
The Journal of Rheumatology
|
September 16, 2020
Prediction of Work Impact in Axial Spondyloarthritis by the Work Instability Scale: A Prospective Cohort Study of 101 Patients
Irina Cucos, Sabrina Dadoun, Charlotte Jacquemin, et al.
Joint Bone Spine
|
October 14, 2019
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
Bruno Fautrel, Manon Belhassen, Christophe Hudry, et al.
Orphanet Journal of Rare Diseases
|
March 12, 2015
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Linda Rossi-Semerano, Bruno Fautrel, Daniel Wendling, et al.
Journal of Medical Economics
|
April 12, 2016
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France
Francis Fagnani, Thao Pham, Pascal Claudepierre, et al.
Joint Bone Spine
|
November 1, 2019
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
Bruno Fautrel, Manon Belhassen, Christophe Hudry, et al.
Annals of the Rheumatic Diseases
|
June 5, 2016
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Georg Schett, Paul Emery, Yoshiya Tanaka, et al.
Current Medical Research and Opinion
|
March 31, 2017
Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)
Bruno Fautrel, Alejandro Balsa, Piet Van Riel, et al.
Page
of 38